Innovent Biologics Technology Limited
Clinical trials sponsored by Innovent Biologics Technology Limited, explained in plain language.
A Chinese biopharmaceutical company developing and commercializing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection shows promise for Diabetes-Related vision loss Results expected Dec 2026 (estimated)
- New hope for advanced tumors? early trial of IBI3026 begins Results expected Dec 2026 (estimated)
- Could a new pill beat the standard for gout? large trial underway Results expected Apr 2027 (estimated)
-
Could a new pill beat the standard for gout? large trial underway
Disease control OngoingThis Phase 3 trial tests whether a new drug, tigulixostat, is better than the standard gout medication febuxostat at lowering uric acid levels in Chinese adults with gout. About 600 participants will take one of the two drugs for 24 weeks, then switch to tigulixostat for another …
Phase 3 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New eye injection shows promise for Diabetes-Related vision loss
Disease control OngoingThis study tests a new eye injection called IBI302 for people with diabetic macular edema, a condition that causes vision loss due to diabetes. About 150 adults aged 18-80 with type 1 or 2 diabetes and swelling in the center of the retina will receive either IBI302 or an active c…
Phase 2 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New Weight-Loss drug candidate enters early human testing
Disease control OngoingThis early-stage study is testing a new drug called IBI3032 in 79 adults who are overweight or have obesity. The main goal is to check if the drug is safe and how the body processes it over a 4-week treatment period. Participants receive either the drug or a placebo, and research…
Phase 1 • Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC